The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Jorge A. Garcia
Consultant or Advisory Role - Astellas Pharma
Paul Elson
No relevant relationships to disclose
Matthew M. Cooney
No relevant relationships to disclose
Allison Janine Tyler
No relevant relationships to disclose
Victoria Rezash
No relevant relationships to disclose
Ernest C. Borden
No relevant relationships to disclose
Robert Dreicer
No relevant relationships to disclose